Related references
Note: Only part of the references are listed.Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
Nico Gagelmann et al.
BLOOD ADVANCES (2023)
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
Krishna R. Juluri et al.
BLOOD ADVANCES (2022)
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
Khushnuma Mullanfiroze et al.
BLOOD ADVANCES (2022)
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
Kai Rejeski et al.
BLOOD ADVANCES (2022)
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Kai Rejeski et al.
BLOOD (2021)
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Moazzam Shahzad et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Tania Jain et al.
BLOOD ADVANCES (2020)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)